Skip to main content
Tian Zhang, MD, Oncology, Dallas, TX, Duke University Hospital

TianZhangMDMHS(She/Her)

Oncology Dallas, TX

Genitourinary Oncology

Associate Professor UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center Adjunct Associate Professor, Duke University

Dr. Zhang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Zhang's full profile

Already have an account?

Summary

  • Dr. Tian Zhang is an oncologist in Dallas, TX and is affiliated with UT Southwestern Medical Center. She received her medical degree from Harvard Medical School and has been in practice 14 years. She speaks multiple languages, including Chinese (Mandarin). She specializes in genitourinary cancers with experience in treatment of prostate, renal, bladder, and testicular cancers.

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2010 - 2012
  • Duke University Hospital
    Duke University HospitalInternship, Internal Medicine, 2009 - 2010
  • Harvard Medical School
    Harvard Medical SchoolClass of 2009

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2024
  • TX State Medical License
    TX State Medical License 2021 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2
    Tian Y Zhang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (All... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after ra... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • COVID-19 Vaccines for Patients with Cancer: Benefits Likely Outweigh Risks
    COVID-19 Vaccines for Patients with Cancer: Benefits Likely Outweigh RisksFebruary 27th, 2021
  • Case 1: Non-Muscle Invasive, BCG-Refractory Bladder Cancer
    Case 1: Non-Muscle Invasive, BCG-Refractory Bladder CancerNovember 27th, 2019
  • The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
    The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)September 16th, 2019
  • Join now to see all

Professional Memberships

Other Languages

  • Chinese (Mandarin)

Hospital Affiliations